Document is current
Any future updates will be listed below
-
Authors
Rabian, Florence
Chevret, Sylvie
Gruson, Bérengère
Thépot, Sylvain
Walter-Petrich, Anouk
Braun, Thorsten
Vey, Norbert https://orcid.org/0000-0001-7027-040X
Torregrosa-Diaz, José Miguel
Peterlin, Pierre
Toma, Andrea
D’Aveni, Maud https://orcid.org/0000-0002-5909-2742
Delaunay, Jacques
Legros, Laurence
Droin, Nathalie
Chermat, Fatiha
Lusina, Daniel
Adès, Lionel https://orcid.org/0000-0002-9020-8766
Sapena, Rosa
Solary, Eric https://orcid.org/0000-0002-8629-1341
Fenaux, Pierre
Itzykson, Raphael https://orcid.org/0000-0003-2139-6262
-
Funding
Funding for this research was provided by:
Institut National Du Cancer (INCa-DGOS-INSERM-ITMO Cancer_18008)
- License Information
-
More Information
Article History
Received: 16 March 2024
Accepted: 28 August 2024
First Online: 12 September 2024
Competing interests
: RI has consulted for Amgen, BMS/Celgene, CTI Biosciences (now Sobi) Daiichi-Sankyo, Gilead, Jazz, Karyopharm, Stemline Therapeutics (now Menarini) and Syndax, and received research funding from Abbvie and Janssen, none of which is related to the present work. LL has consulted for Amgen, BMS/Celgene, GSK, Incyte, Novartis and Pfizer, none of which is related to the present work. The other authors declare no conflict of interest.
